|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 9/03/20 BioSig Technologies, Inc. 8-K:1,9 9/02/20 12:188K Federal Filings, LLC/FA |
Document/Exhibit Description Pages Size 1: 8-K Current Report HTML 24K 2: EX-10.1 Material Contract HTML 18K 8: R1 Document And Entity Information HTML 46K 10: XML IDEA XML File -- Filing Summary XML 12K 7: XML XBRL Instance -- biosig20200903_8k_htm XML 13K 9: EXCEL IDEA Workbook of Financial Reports XLSX 6K 4: EX-101.DEF XBRL Definitions -- bsgm-20200902_def XML 33K 5: EX-101.LAB XBRL Labels -- bsgm-20200902_lab XML 63K 6: EX-101.PRE XBRL Presentations -- bsgm-20200902_pre XML 32K 3: EX-101.SCH XBRL Schema -- bsgm-20200902 XSD 13K 11: JSON XBRL Instance as JSON Data -- MetaLinks 12± 19K 12: ZIP XBRL Zipped Folder -- 0001185185-20-001285-xbrl Zip 15K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM i 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): i September 2, 2020
i BioSig Technologies, Inc.
(Exact name of registrant as specified in its charter)
| i Delaware | i 26-4333375 | |
| (State or other jurisdiction | (Commission File Number) | (IRS Employer |
| of incorporation) |
| Identification No.) |
| i 54 Wilton Road, 2nd Floor i Westport, i Connecticut |
| i 06880 |
| (Address of principal executive offices) |
| (Zip Code) |
i (203) i 409-5444
(Registrant’s telephone number, including area code)
|
N/A (Former name or former address, if changed since last report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
i ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
i ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
i ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
i ☐ Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
| Trading Symbol(s) |
| Name of exchange on which registered |
| i Common Stock, par value $0.001 per share |
| i BSGM |
| The NASDAQ Capital Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company i ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 1.01 Entry Into a Material Definitive Agreement.
On September 2, 2020, ViralClear Pharmaceuticals, Inc. (“ViralClear”), a majority-owned subsidiary of BioSig Technologies, Inc. (the “Company”), as successor-in-interest to Trek Therapeutics, PBC (“Trek”), entered into a second amendment (the “Amendment”) to an assignment and license agreement, as amended (the “Original Agreement”), with Vertex Pharmaceuticals Incorporated (“Vertex”), originally entered into on July 12, 2016, by and among Vertex and Trek. ViralClear is developing Merimepodib for the treatment of COVID-19.
Among other modifications to the Original Agreement, pursuant to the Amendment, all references to “TREKtx” will be amended to refer to ViralClear. Additionally, the Amendment eliminates the first two milestone events (the first being the initiation of a Phase 2 clinical trial of a product in a non-HCV indication in the field of use, and the second being the initiation of a Phase 3 clinical trial of a product in a non-HCV indication in the field of use) and the associated milestone payments (totaling $6 million) listed in the Original Agreement. The amendment enables ViralClear to execute on their program for COVID-19. The Amendment now has only two milestone events and associated milestone payments. Further, the running royalties rate has been increased in the Amendment to 6%, from 5% in the Original Agreement.
The foregoing description of the terms and conditions of the Amendment is qualified in its entirety by reference to the full text of the Amendment, a copy of which is attached hereto as Exhibit 10.1, and which is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
|
Exhibit Number |
|
Description |
|
10.1 |
|
|
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
Date: September 3, 2020 |
By: |
|
|
|
|
|
Name: Kenneth L. Londoner |
|
|
|
|
Title: Executive Chairman |
|
| This ‘8-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 9/3/20 | |||
| For Period end: | 9/2/20 | 8-K | ||
| 7/12/16 | ||||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 11/13/23 BioSig Technologies, Inc. 424B5 1:504K M2 Compliance LLC/FA 9/15/23 BioSig Technologies, Inc. 424B5 1:382K Federal Filings, LLC/FA 8/18/23 BioSig Technologies, Inc. 424B5 1:369K Federal Filings, LLC/FA 6/28/22 BioSig Technologies, Inc. 424B5 1:445K Federal Filings, LLC/FA 6/23/22 BioSig Technologies, Inc. 424B5 1:460K Federal Filings, LLC/FA 5/17/22 BioSig Technologies, Inc. 424B5 1:364K Federal Filings, LLC/FA 3/22/22 BioSig Technologies, Inc. 424B5 1:355K Federal Filings, LLC/FA 7/06/21 BioSig Technologies, Inc. 424B5 1:451K Federal Filings, LLC/FA 7/01/21 BioSig Technologies, Inc. 424B5 1:443K Federal Filings, LLC/FA 12/31/20 BioSig Technologies, Inc. S-3 3:357K Federal Filings, LLC/FA 11/05/20 BioSig Technologies, Inc. 10-Q 9/30/20 73:7.5M Federal Filings, LLC/FA |